Genentech Files Complaint Against Centus Over Proposed Bevacizumab Biosimilar

Shots:

• Genentech filed a complaint in the Eastern District of Texas alleging that the proposed biosimilar to Avastin (bevacizumab) product infringes 10 US patents
• Genentech alleges that Centus and partners failed to disclose sufficient information about the proposed biosimilar to enable Genentech to do a sufficient analysis of potential patent infringements
• Centus has a BLA under review with the FDA for the bevacizumab biosimilar candidate FKB238, and the company has filed a notice of intent to commercialize the agent

Click here ­to­ read full press release/ article | Ref: BigMoleculeWatch | Image: Genentech